The latest method of combining trametinib

Trametinib (Trametinib) is often used in combination with dabrafenib to enhance the treatment of malignant melanoma. This combination treatment regimen has been shown to have significant efficacy in some patients. New approaches include individualizing treatment based on a patient's genetic mutations. Genetic testing can determine whether a patient has the BRAF V600E or V600K mutation, as well as other related mutations. Depending on the type of mutation, an appropriate combination of targeted drugs can be selected.

In addition, some studies have also explored the combination of trametinib and dabrafenib with other immunotherapy drugs. Adding a MEK inhibitor, such as cobimetinib, to a BRAF inhibitor can alleviate one resistance pathway, increase response rate, and improve overall survival (OS) without associated cumulative toxicity. In a recent exploratory analysis of survival data from selected clinical trials with long-term follow-up of metastatic melanoma, mean survival curves obtained by weighted averaging showed that combination therapy with a BRAF plus MEK inhibitor was significantly better than BRAF inhibition alone in first-line therapy as well as in second-line or higher-line therapy. The superiority of BRAF combined with MEK inhibitors remained consistent in terms of progression-free survival (PFS) and OS with follow-up up to 28 months.

On the other hand,MEK monotherapy produces only limited efficacy (similar to chemotherapy as second-line or above). The same analysis showed superiority of the BRAF plus MEK inhibitor combination during the first 6 months after treatment initiation. After 6 months, PD-1 blockers were found to have clear advantages when used alone or in combination with CTLA-4 blockers. These findings are important and reflect the clinical phenomenon of acquired resistance, which is common with MAP kinase inhibition, occurring in two phenomena: a strong decrease in the respective mean survival curves at 6 months of treatment, and primary resistance, which is common with immune checkpoint inhibition. These results demonstrate the efficacy of a therapeutic approach that provides the expected switch from MAP kinase inhibition to immune checkpoint blockade to achieve the maximum benefit of both treatment strategies. For this reason, daily clinical practice data from combined use of BRAF and MEK inhibitors may help improve understanding of this disease.

The original drug of Trametinib has been launched in China and is included in the scope of medical insurance, but it may only be available to patients who meet the indications. The price of 2 mg*30 tablets is more than RMB 10,000. The original drug of Trametinib sold overseas, with the price of 2 mg*30 tablets, is more than RMB 7,000 (the price may fluctuate due to exchange rates). There are also generic trametinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a 2mg*30 tablet of a generic drug produced by a Laos pharmaceutical factory is more than 2,000 yuan (the price may fluctuate due to the exchange rate).